Sarepta Therapeutics (NASDAQ:SRPT) had its target price reduced by Robert W. Baird from $202.00 to $181.00 in a research note published on Tuesday morning, The Fly reports. They currently have an outperform rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $267.00 price objective (up from $160.00) on shares of Sarepta Therapeutics in a research report on Tuesday. Bank of America lowered their price objective on Sarepta Therapeutics from $200.00 to $189.00 and set a buy rating on the stock in a research report on Tuesday. BidaskClub cut Sarepta Therapeutics from a hold rating to a sell rating in a research report on Wednesday, August 14th. Janney Montgomery Scott lowered their price objective on Sarepta Therapeutics from $200.00 to $175.00 and set a buy rating on the stock in a research report on Tuesday. Finally, Zacks Investment Research raised Sarepta Therapeutics from a hold rating to a buy rating and set a $130.00 price objective on the stock in a research report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have given a buy rating to the stock. The stock has an average rating of Buy and an average target price of $197.78.
SRPT stock opened at $95.07 on Tuesday. Sarepta Therapeutics has a twelve month low of $90.24 and a twelve month high of $165.87. The company has a quick ratio of 7.84, a current ratio of 8.81 and a debt-to-equity ratio of 0.44. The stock has a market cap of $7.59 billion, a P/E ratio of -17.41 and a beta of 2.01. The business’s 50-day moving average price is $140.56 and its 200-day moving average price is $130.38.
In other Sarepta Therapeutics news, Director Richard Barry purchased 5,000 shares of the stock in a transaction that occurred on Tuesday, August 20th. The shares were bought at an average cost of $99.32 per share, with a total value of $496,600.00. Following the acquisition, the director now owns 3,182,065 shares in the company, valued at $316,042,695.80. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Douglas S. Ingram purchased 16,252 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average cost of $123.07 per share, for a total transaction of $2,000,133.64. Following the completion of the acquisition, the chief executive officer now owns 424,405 shares in the company, valued at approximately $52,231,523.35. The disclosure for this purchase can be found here. Over the last three months, insiders purchased 26,252 shares of company stock worth $3,109,234. 6.60% of the stock is owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Evolution Wealth Advisors LLC bought a new stake in Sarepta Therapeutics in the 2nd quarter worth approximately $25,000. Trust Co. of Vermont increased its position in shares of Sarepta Therapeutics by 2,125.0% during the 2nd quarter. Trust Co. of Vermont now owns 178 shares of the biotechnology company’s stock valued at $27,000 after purchasing an additional 170 shares during the last quarter. Steward Partners Investment Advisory LLC bought a new position in shares of Sarepta Therapeutics during the 2nd quarter valued at approximately $32,000. Lindbrook Capital LLC bought a new position in shares of Sarepta Therapeutics during the 1st quarter valued at approximately $35,000. Finally, Quadrant Capital Group LLC bought a new position in shares of Sarepta Therapeutics during the 1st quarter valued at approximately $51,000. 93.59% of the stock is currently owned by institutional investors.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Featured Story: What is a Stop Order?
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.